



Ocrevus in the UAE

The MoHAP named-patient coordination pathway — indicative 2026

NEUROLOGY · RELAPSING MS & PRIMARY-PROGRESSIVE MS

The clinical situation

Ocrevus (ocrelizumab) is an IV anti-CD20 monoclonal antibody FDA-approved for relapsing forms of multiple sclerosis and primary-progressive MS. Manufactured by Genentech/Roche. Standard regimen is 300 mg IV x2 as initial loading (two weeks apart), then 600 mg IV every 6 months. An SC formulation (Ocrevus Zunovo) is also available. Pre-treatment workup covers hepatitis B screening, vaccination review (including live vaccines before depletion), immunoglobulins, and infection screen per FDA labelling.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your neurologist documents MS subtype, MRI review, prior DMTs, and Ocrevus rationale.
- 2 Baseline screening.** Hepatitis B panel, immunoglobulins, vaccination review and update, baseline infection screen per FDA labelling.
- 3 MoHAP named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, dosing calendar, infusion-facility plan, and chain-of-custody commitment; DHA/DoH approvals align where applicable.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with validated 2–8°C shipment.
- 5 Arrival & first infusion.** Infusion facility administers Day 1 and Day 15 loading doses with premedication; subsequent 6-monthly maintenance follows.

Indicative economics

Reference US cash-pay range: USD 65,000–80,000 per year of Ocrevus (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete MoHAP application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody from Genentech/Roche authorised distribution. **Documentation.** Physician kit tailored to MoHAP / DHA / DoH review, with anti-CD20 class safety annex. **Logistics.** Validated cold-chain internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through each six-month cycle. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Ocrevus × UAE first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/ocrevus-uae.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team